What IntraBio’s IB1001-304 Phase III trial could reveal about CACNA1A treatment
IntraBio’s Phase III CACNA1A trial is enrolling, with October recruitment completion targeted as levacetylleucine enters a pivotal test.
Pharma & Biotech
Pharma & Biotech
IntraBio leverages prior Niemann-Pick approval to seek FDA expansion of levacetylleucine into Ataxia-Telangiectasia
IntraBio files the first-ever FDA application for an A-T therapy. Analyse the Phase III evidence, regulatory pathway, and what approval would mean.